Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates

D T McManus, A H Patterson, P Maxwell, M W Humphreys, N H Anderson

Abstract

Aim—to develop a method for the detection of amplification of the erbB2 oncogene in breast cancer fine needle aspirates using fluorescence in situ hybridisation (FISH) and to compare amplification with immunohistochemical detection of the erbB2 protein.

Methods—A digoxigenin labelled probe to the erbB2 gene was hybridised to 15 aspirates prepared from operative breast cancer specimens. A chromosome 17 centromere probe was also hybridised to the aspirates either separately or in combination with the erbB2 probe. The aspirates were scored for erbB2 amplification and chromosome 17 centromere number. Subsequently, paraffin wax embedded sections of the tumours were stained with the antibody CB11 and scored for the presence of membrane staining.

Results—Three of the 15 tumour aspirates showed high level amplification of erbB2 detected by FISH. These three tumours also showed chromosome 17 polysomy and diffuse membrane staining by immunohistochemistry.

Conclusions—FISH can be used to detect erbB2 amplification in fine needle aspirates and results correlate with conventional immunohistochemical staining. Difficulties were encountered in the visualisation of the signals in non-amplified cases without the use of specialised digital imaging.

Key words: breast cancer; fine needle aspirates; fluorescence in situ hybridisation; erbB2

The erbB2 oncogene is situated on the long arm of chromosome 17 at 17q21 and encodes a putative membrane tyrosine kinase with homology to a truncated epidermal growth factor receptor. The gene is amplified in a variety of cancers, including breast cancer; amplification of the gene has been linked closely to p185 protein overproduction, detection of which is used as a marker of erbB2 amplification. The erbB2 probe allowed comparisons to be made between erbB2 copy number and chromosome 17 centromere number. The erbB2 oncogene occurs in ~21% of breast cancers, and that such overexpression is also seen in ductal carcinoma in situ, particularly comedo and other high grade subtypes. Controversy surrounds the value of erbB2 as a prognostic marker in relation to responses to chemotherapy and it has been suggested that the investigation of patients receiving neoadjuvant chemotherapy might help to resolve this issue. In this context, preoperative detection of erbB2 amplification in breast cancer using fine needle aspirates might be of particular relevance and could be useful clinically. Aspirates contain whole unfixed tumour cell nuclei and in many ways are ideal specimens for fluorescence in situ hybridisation (FISH) analysis.

A rapid and simple qualitative method for detecting amplification of the erbB2 gene in breast cancer fine needle aspirates is described and the results are correlated with conventional immunohistochemical staining of paraffin wax embedded sections with antibody CB11. Hybridisation of a chromosome 17 centromere probe allowed comparisons to be made between erbB2 copy number and chromosome 17 centromere number.

Materials and methods

To confirm the specificity of the chromosome 17 centromere and erbB2 probes they were co-hybridised to metaphase spreads prepared from a normal individual by conventional methods.

Fine needle aspirates were prepared from 15 unfixed operative breast cancer specimens. The aspirates were smeared on to a small area of APES coated slides. The slides were denatured in 70% formamide, 2× saline sodium citrate (SSC) at 70°C, plunged into 70% ice cold ethanol, transferred to ethanol at room temperature, and allowed to dry. A digoxigenin labelled probe to the erbB2 locus (Oncor, Durham, UK) was prewarmed to 37°C and hybridised overnight at 37°C in a moist chamber. The stringency washes in 50% formamide, 1× SSC, at 37°C, were followed by a one step indirect detection method using antidigoxigenin fluorescein isothiocyanate (FITC) or antidigoxigenin rhodamine for the single and dual hybridisation experiments, respectively.

For the dual hybridisation experiments, a centromere probe directly labelled with FITC (Boehringer Mannheim, Lewes, Sussex, UK) was used. The slide and the centromere probes were denatured separately, the centromere and the erbB2 probes were then applied sequentially. The erbB2 probe was detected using antidigoxigenin rhodamine (at a dilution of 1/200).
In seven cases, the erbB2 probe was detected by antidigoxigenin FITC and a digoxigenin labelled centromere probe (Boehringer Mannheim) was hybridised separately to a different slide from the same case.

The counterstain used in all specimens was DAPI (4,5 diamino-2-phenyl-indole. The slides were examined at ×1000 magnification using a Leica epifluorescence microscope with a triple band pass filter set. Fluorescence signals were collected through a Photometrics (Tucson, Arizona, USA) black and white cooled charged coupled device (CCD) camera linked to an Apple Mac (Apple Computer Company, Middlesex, UK) computer running the Vysis smart capture system, enabling the capture of digitised colour fluorescence images. The FITC, rhodamine, and DAPI signals were viewed and captured using the respective excitation filters. All three channels were captured consecutively and pseudocoloured to their respective primary colours (rhodamine, red; FITC, green; DAPI, blue) and automatically merged using the smart capture software.

Paraffin wax embedded sections of the corresponding cancers were stained with monoclonal antibody CB11 (NovoCastra, Newcastle upon Tyne, UK) at a 1/50 dilution after microwave antigen retrieval, using 0.1 M citrate buffer, pH 6.0, for 20 minutes. A standard streptavidin biotin complex method (Dako, Ely, Cambridgeshire, UK) was used with peroxidase/diaminobenzidine as chromogen.

**Results**

Dual hybridisation of the chromosome 17 centromere/erbB2 probe to metaphase spreads from a normal individual (fig 1A) confirmed the specificity of both probes under the stringency conditions described.

As expected, the signal intensity of the erbB2 probe was less than that of the chromosome 17 centromere probe, so that fewer cells showed two clearly visible signals in the aspirates not showing amplification (fig 1B).

Three of the 15 aspirates showed high level erbB2 amplification as detected by FISH. In the amplified cases, the amplified erbB2 signals were evident as clusters of intranuclear pink or green dots, depending on the detection system (fig 1C and D), and in keeping with amplification by a mechanism involving homogenously staining regions. These three specimens were also polysomic for chromosome 17. It was possible to discern extra copies of erbB2 in other aspirates polysomic for chromosome 17 but, on
inspection, it was easy to distinguish these from the specimens showing high level amplification.

Three of the 15 tumours showed diffuse staining of the tumour cell membranes with antibody CB11 (fig 1E). The other 12 tumours showed no evidence of immunoreactivity. The same three tumours also showed evidence of erbB2 amplification by FISH in the aspirates.

**Discussion**

Amplification of the erbB2 gene can be detected by solid matrix blotting techniques, such as dot blots and Southern blotting, or the differential polymerase chain reaction, using constitutively expressed genes such as actin as an internal control. However, these techniques may underestimate copy number, because the final signal gives an average estimation of the level of amplification in the sample. Amplified signals from the tumour cells might be diluted considerably by contaminating stromal cells that have a normal copy number. Therefore, such approaches are more likely to produce a continuous distribution of amplification levels, with associated difficulties in selecting a threshold for a positive result. FISH is emerging as the most sensitive and reliable technique for detecting amplification of the erbB2 oncogene, at least in paraffin wax embedded material. Moreover, FISH may also allow studies into tumour heterogeneity with respect to gene amplification.

In our investigation, amplified cases contained multiple copies of the erbB2 locus, clustered together, in keeping with amplification in the form of intrachromosomal homogeneously staining regions, rather than double minutes. Such cases were easily separated by inspection from aneuploid cases containing several copies only of the erbB2 locus. Comparison with the 17 centromere copy number was helpful in this respect but not essential. Only the three cases with multiple copies of the gene showed diffuse membrane staining with antibody CB11. A quantitative estimation of an erbB2 to chromosome 17 centromere copy number ratio, as in previous investigations was not necessary. Such cases were easily separated by inspection, it was easy to distinguish these from the specimens showing high level amplification.

The FISH assay is completed in two days and is not much more labour intensive than immunohistochemical techniques. The procedure could be completed within a single working day if necessary. The commercial probe is very expensive, but the costs could be reduced greatly if probes were purified and labelled in house. The specialised fluorescence imaging systems are very expensive and time consuming to use.

In conclusion, our pilot study has shown that amplification of the erbB2 oncogene can be detected by FISH using fine needle aspirates from resected breast cancers. The technique should be readily applicable to clinical fine needle aspirates. Previously, we have detected numerical chromosomal abnormalities in fine needle aspirates from palpable tumours and radiologically guided aspirates obtained from the screening programme. Amplification of the gene correlates with protein overproduction, detected by immunohistochemistry as diffuse membrane staining in paraffin wax embedded sections. Amplification is readily detectable qualitatively by inspection without dual hybridisation and calculation of an erbB2 to chromosome 17 centromere copy number ratio.

This work was supported by grants from Action Cancer and Cancer Research Trust to DT McManus and NH Anderson, respectively.